• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ARGATROBAN Drug Record

  • Summary
  • Interactions
  • Claims
  • ARGATROBAN chembl:CHEMBL1166 Approved

    Alternate Names:

    ACOVA
    GN-1600
    MCI-9038
    GN1600
    DK-7419
    ARGATROBAN MONOHYDRATE
    ARGATROBAN HYDRATE
    ARGATROBAN IN SODIUM CHLORIDE
    ARGATROBAN
    ARGATROBAN IN DEXTROSE
    MD-805
    ARGATROBAN ANHYDROUS
    AGO766
    chembl:CHEMBL1166
    chemidplus:74863-84-6
    pubchem.compound:92722
    drugbank:00278
    rxcui:1546207

    Drug Info:

    FDA Approval approved
    Drug Class Small molecule
    Drug Indications anticoagulant
    (1 More Sources)

    Publications:

    Serebruany et al., 1998, A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study., J. Thromb. Thrombolysis
    Sakai et al., 1999, Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model., Cardiovasc Surg
    Jang et al., 1999, A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study., J. Am. Coll. Cardiol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Matsuo et al., 1995, Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban., J. Thromb. Thrombolysis
    Kawada et al., 1999, Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture., Jpn. J. Thorac. Cardiovasc. Surg.
    Kato et al., 1999, In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist., Eur. J. Pharmacol.
  • ARGATROBAN   F2

    Interaction Score: 9.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Argatroban
    Mechanism of Interaction Thrombin inhibitor

    PMIDs:
    10608050 10353669 10362188 11752352 10608016 10226408


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • ARGATROBAN   F2R

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10611442


    Sources:
    NCI

  • TdgClinicalTrial: ARGATROBAN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications anticoagulant
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • NCI: ARGATROBAN

    • Version: 14-September-2017

    Alternate Names:
    C28833 NCI drug code

    Drug Info:

    Publications:
    Kato et al., 1999, In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist., Eur. J. Pharmacol.

  • TTD: Argatroban

    • Version: 2020.06.01

    Alternate Names:
    D07UWV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1166

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1166

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21